Replies to post #233839 on Biotech Values

[DewDiligence]

ANNX -23%/AH on purportedly promising phase-2 data in HD:

https://finance.yahoo.com/news/annexon-biosciences-reports-promising-interim-210500719.html

NfL, a protein component of the neuronal cytoskeleton, has been shown to increase in the CSF with disease severity in HD patients. Interim data assessing NfL from patients evaluable as of the cutoff date of October 17, 2021 (n=16) who completed 24 weeks of treatment showed that mean plasma and CSF NfL levels remained generally consistent and were comparable to NfL levels described in published natural history data for HD patients [i.e. comparable to treatment with a placebo].

Published data suggest that in slowly progressive neurodegenerative diseases like HD, synapse loss is associated with progressive functional decline, preceding the loss of neurons and NfL changes. As such, changes in NfL may require treatment durations longer than six months…

Uh huh, LOL.

The stock is now down 50% from its 2020 IPO price of $17.00.